 Nes Ziona, Israel, Nov. 03, 2020 GLOBE NEWSWIRE -- Enlivex Therapeutics Ltd. Nasdaq: ENLV, the Company, a clinical-stage immunotherapy company, today reported that the Israeli Ministry of Health authorized the initiation of a proposed Company-sponsored Phase IIb clinical trial evaluating AllocetraTM, in sepsis patients. 